FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to laboratory methods for studying hemostasis, and concerns the determination of blood plasma coagulation parameters - thrombin activity, plasma recalcification time and plasma tolerance to heparin. The fluorescence method is used in the visible range of 420-600 nm in the presence of compounds of the borondipyrine series (BODIPY), such as 4,4-difluoro-8-phenyl-1,3,5,7-tetramethyl-2,6-diethyl-4- boron-3a,4a-diaza-s-indacene; 4,4-difluoro-8-(para-dimethylaminophenyl)-1,3,5,7-tetramethyl-2,6-diethyl-4-boron-3a,4a-diaza-8-indacene; 4,4-difluoro-8-(di-orthomethylphenyl)-1,3,5,7-tetramethyl-2,6-diethyl-4-boron-3a,4a-diaza-s-indacene, whose fluorescence depends on the presence of biomolecules fibrinogen. The dependence of the fluorescence intensity at the maximum emission of BODIPY is recorded, then a coagulation curve of the plasma sample is obtained. In this case, the study is stopped when a stable plateau is reached on the fluorescence change curve. Next, the coagulation curve is analyzed, while three sections are observed and analyzed on the coagulation curve: an upper plateau, a descending section and a lower plateau. At the same time, based on the length of the upper plateau (tlag), the plasma tolerance to heparin is determined. Then a tangent is drawn to the descending section of the coagulation curve, which forms the angle of inclination φ to the y-axis: tg φ, which is proportional to thrombin activity. The plasma recalcification time is obtained by extrapolating the tangent to the descending portion of the coagulation curve to the x-axis (time), cutting off the fibrin clot stabilization step.
EFFECT: invention provides for the expansion of technical capabilities by determining the three indicated indicators of blood plasma coagulation and increasing the sensitivity and accuracy of the process of their determination.
1 cl, 1 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
METHOD FOR EVALUATING PLASMA HAEMOSTASIS | 2023 |
|
RU2816538C1 |
METHOD FOR OPTIMIZING LABORATORY DIAGNOSIS OF THROMBINEMIA IN PATIENTS WITH COVID-19 INFECTION | 2022 |
|
RU2789822C1 |
PHOSPHOLIPIDE FLUORESCENT PROBE AND TEST-SYSTEM FOR DETERMINATION OF ACTIVITY OF A2 PHOSPHOLIPASE IN BLOOD SERUM | 2012 |
|
RU2517538C1 |
DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
METHOD OF SCREENING EXAMINATION FOR DETECTION OF RISK GROUPS OF DEVELOPING HYPERCOAGULATION STATE IN CONDITIONS OF EXPEDITIONARY WORK IN THE ARCTIC | 2020 |
|
RU2767891C2 |
METHOD OF DETERMINING THROMBIN COMPLEMENTARITY SYSTEM ACTIVATION PATHWAY | 2019 |
|
RU2717946C1 |
CARBORANE DERIVATIVES OF 4,4-DIFLUORO-4-BORA-3α,4α-DIASE-s-INDACENE SHOWING ANTI-TUMOR ACTIVITY | 2022 |
|
RU2789401C1 |
METHOD FOR DETERMINING FIBRINOGEN AND FUNCTIONALITY EVALUATION THEREOF | 2020 |
|
RU2732388C1 |
SCREENING-TEST OF DETERMINING COAGULATION CONTACT WAY (STOKPK) | 2017 |
|
RU2660706C1 |
Authors
Dates
2022-12-22—Published
2020-10-05—Filed